Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.42 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.41 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.41 |
| ▸ | PNMT | P11086 | 1/20 | 0.39 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283453 | 0.81 | CYP1A2 (0.46) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL3277734 | 0.80 | CYP1A2 (0.49) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL3276601 | 0.80 | CLPP (0.42) | CYP1A2SIGMAR1PTGER2PNMTCYP2D6 | |
| SCHEMBL3276248 | 0.78 | CYP1A2 (0.43) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL3277742 | 0.74 | CYP2D6 (0.48) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2110623 | 0.73 | CYP1A2 (0.47) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL3283649 | 0.72 | MAPK1 (0.41) | — | |
| SCHEMBL6436620 | 0.72 | CYP2D6 (0.51) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL3276408 | 0.71 | CYP2D6 (0.51) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B | |
| SCHEMBL2110909 | 0.70 | KMT2A (0.43) | CYP1A2SIGMAR1TMEM97ADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2123644-B1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2014-12-17 | — | — | EP | disclosed |
| US-8247403-B2 | Benzoxazepine derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-08-21 | — | — | US | disclosed |
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2123644-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2009-11-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087418-A1 | BENZOXAZEPINE DERIVATIVES AND USE THEREOF | HTR2C, HTR5A, HTR2B | CYP1A2 156/4885SIGMAR1 809/4885TMEM97 890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.